Post-Conference Perspectives: Understanding HER2-Low Breast Cancer

Experts Sandra M. Swain, MD, and Zahi Mitri, MD, MS, reflect on HER2-low breast cancer as a subset of disease and discuss novel therapeutic agents that may improve patient outcomes in this setting.

EP. 1: Current Landscape of HER2 Testing in Breast Cancer

December 9th 2021

Shared insight on the current state of HER2 classification and testing and in breast cancer, with respect to how it may influence future treatment approaches.

EP. 2: Strategies in Identifying and Stratifying HER2 Status in Breast Cancer

December 9th 2021

Focused discussion on the methods used to identify a patient’s HER2 status and why it is important to investigate in patients with breast cancer.

EP. 3: Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates

December 9th 2021

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

EP. 4: HER2-low Breast Cancer: Practical Applications of ADC Therapy

December 9th 2021

Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.